Argus analyst David Toung upgraded Novartis (NVS) to Buy from Hold with an $180 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis price target raised to CHF 110 from CHF 92 at Berenberg
- Controversial Prasad leaving FDA, NYT reports
- Novartis shareholders approve all resolutions proposed by Board of Directors
- Best ETFs to Invest In, According to AI Analyst, 3/4/2026
- Trump Trade: U.S. stocks tumble, oil prices surge after strikes on Iran